Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma

被引：20

作者：

Lubitz, Carrie C. ^{[1
,2
]}

Zhan, Tiannan ^{[2
]}

Gunda, Viswanath ^{[1
]}

Amin, Salma ^{[1
]}

Gigliotti, Benjamin J. ^{[3
]}

Fingeret, Abbey L. ^{[1
]}

Holm, Tammy M. ^{[1
]}

Wachtel, Heather ^{[1
]}

Sadow, Peter M. ^{[4
]}

Wirth, Lori J. ^{[3
]}

Sullivan, Ryan J. ^{[3
]}

Panka, David J. ^{[5
]}

Parangi, Sareh ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA

[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[4] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[5] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA

来源：

THYROID | 2018年 / 28卷 / 03期

基金：

美国国家卫生研究院;

关键词：

papillary thyroid cancer; thyroid cancer; BRAF(V600E); biomarker; circulation tumor cells; BRAF V600E MUTATION; TUMOR-CELLS; METASTATIC MELANOMA; ACTIVE SURVEILLANCE; CANCER INCIDENCE; ASSOCIATION; RISK; DNA; DABRAFENIB; RECURRENCE;

D O I：

10.1089/thy.2017.0322

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background:BRAF(V600E) is the most common mutation in papillary thyroid carcinoma (PTC) and can be associated with aggressive disease. Previously, a highly sensitive blood RNA-based BRAF(V600E) assay was reported. The objective of this study was to assess the correlation of BRAF(V600E) circulating tumor RNA levels with surgical and medical treatment. Methods: Circulating BRAF(V600E) levels were assessed in (i) a murine model of undifferentiated (anaplastic) thyroid carcinoma with known BRAF(V600E) mutation undergoing BRAF(V600E)-inhibitor (BRAFi) treatment, and (ii) in 111 patients enrolled prior to thyroidectomy (n=86) or treatment of advanced recurrent or metastatic PTC (n=25). Blood samples were drawn for BRAF(V600E) analysis before and after treatment. Testing characteristics were assessed and positivity criteria optimized. Changes in blood BRAF(V600E) values were assessed and compared to clinical characteristics and response to therapy. Results: In a murine model of anaplastic thyroid carcinoma with BRAF(V600E) mutation, blood BRAF(V600E) RNA correlated with tumor volume in animals treated with BRAFi. In tissue BRAF(V600E)-positive (n=36) patients undergoing initial surgery for PTC, blood BRAF(V600E) levels declined postoperatively (median 370.0-178.5 fg/ng; p=0.002). In four patients with metastatic or poorly differentiated thyroid carcinoma receiving targeted therapies, blood BRAF(V600E) declined following therapy and corresponded with radiographic evidence of partial response or stable disease. Conclusions: This study shows the correlation of blood BRAF(V600E) levels in response to treatment in both an established animal model of thyroid cancer and in patients with BRAF(V600E)-positive tumors with all stages of disease. This assay represents an alternative biomarker in patients with positive thyroglobulin antibodies, and tumors, which do not express thyroglobulin.

引用

页码：328 / 339

页数：12

共 51 条

[1] Multicenter Clinical Experience With the Afirma Gene Expression Classifier [J].

Alexander, Erik K. ;

Schorr, Melanie ;

Klopper, Joshua ;

Kim, Caroline ;

Sipos, Jennifer ;

Nabhan, Fadi ;

Parker, Charles ;

Steward, David L. ;

Mandel, Susan J. ;

Haugen, Bryan R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (01) :119-125

[2] Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR [J].

Ashida, Atsuko ;

Sakaizawa, Kaori ;

Mikoshiba, Asuka ;

Uhara, Hisashi ;

Okuyama, Ryuhei .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (05) :981-988

[3] The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis [J].

Barbaro, Daniele ;

Incensati, Roberto Mario ;

Materazzi, Gabriele ;

Boni, Giuseppe ;

Grosso, Mariano ;

Panicucci, Erica ;

Lapi, Paola ;

Pasquini, Cristina ;

Miccoli, Paolo .

ENDOCRINE, 2014, 45 (03) :462-468

[4] Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial [J].

Brose, Marcia S. ;

Cabanillas, Maria E. ;

Cohen, Ezra E. W. ;

Wirth, Lori J. ;

Riehl, Todd ;

Yue, Huibin ;

Sherman, Steven I. ;

Sherman, Eric J. .

LANCET ONCOLOGY, 2016, 17 (09) :1272-1282

[5] Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression [J].

Chang, Gregory A. ;

Taclepalli, Jyothirmayee S. ;

Shao, Yongzhao ;

Zhang, Yilong ;

Weiss, Sarah ;

Robinson, Eric ;

Spittle, Cindy ;

Furtado, Manohar ;

Shelton, Dawne N. ;

Karlin-Neumann, George ;

Pavlick, Anna ;

Osman, Iman ;

Polsky, David .

MOLECULAR ONCOLOGY, 2016, 10 (01) :157-165

[6] BRAFV600E Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis [J].

Chen, Yufei ;

Sadow, Peter M. ;

Suh, Hyunsuk ;

Lee, Kyu Eun ;

Choi, June Young ;

Suh, Yong Joon ;

Wang, Tracy S. ;

Lubitz, Carrie C. .

THYROID, 2016, 26 (02) :248-255

[7] Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].

Cooper, David S. ;

Doherty, Gerard M. ;

Haugen, Bryan R. ;

Kloos, Richard T. ;

Lee, Stephanie L. ;

Mandel, Susan J. ;

Mazzaferri, Ernest L. ;

McIver, Bryan ;

Pacini, Furio ;

Schlumberger, Martin ;

Sherman, Steven I. ;

Steward, David L. ;

Tuttle, R. Michael .

THYROID, 2009, 19 (11) :1167-1214

[8] AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYRIOD CANCER [J].

Davies, Louise ;

Morris, Luc G. T. ;

Haymart, Megan ;

Chen, Amy Y. ;

Goldenberg, David ;

Morris, John ;

Ogilvie, Jennifer B. ;

Terris, David J. ;

Netterville, James ;

Wong, Richard J. ;

Randolph, Gregory .

ENDOCRINE PRACTICE, 2015, 21 (06) :686-696

[9]

Denis MG, 2016, J CLIN ONCOL S, V34

[10] BRAF: A Tool in the Decision to Perform Elective Neck Dissection? [J].

Dutenhefner, Simone E. ;

Marui, Suemi ;

Santos, Andre B. O. ;

de Lima, Erika Urbano ;

Inoue, Milton ;

Brandao Neto, Jose S. ;

Shiang, Christina ;

Fukushima, Julia T. ;

Cernea, Claudio R. ;

Friguglietti, Celso U. M. .

THYROID, 2013, 23 (12) :1541-1546

← 1 2 3 4 5 6 →